Single agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group

British Journal of Cancer

Volumn 73, Issue 3, 1996, Pages 403-405

  Kaplan, S ^a   Hanauske, A R ^b   Pavlidis, N ^c   Bruntsch, U ^d   Te Velde, A ^e   Wanders, J ^e   Heinrich, B ^b   Verweij, J ^f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF IOANNINA   (Greece)

^d 5Th Med Department   (Germany)

^e EORTC New Drug Development Office   (Netherlands)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Non small cell lung cancer; Phase II; Rhizoxin

Indexed keywords

ANTINEOPLASTIC AGENT; RHIZOXIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0030032650     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.70     Document Type: Article

References (10)

1. BAKOWSKI MT AND CROUCH JC. (1983). Chemotherapy for non-small-cell-lung cancer. A reappraisal and look to the future. Cancer Treat. Rev., 10, 159-172.
2. BISSETT D, GRAHAM MA, SETANOIANS A, CHADWICK GA, WILSON P, KOJER IJ, HENRAR R, SCHWARTSMANN G, CASSIDY J, KAYE SB AND KERR DJ. (1992). Phase I and pharmacokinetic study of rhizoxin. Cancer Res., 52, 2894-2898.
3. BONOMI PD, FINKELSTEIN DM AND RUCKDESCHEL JC. (1989). Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell-lung cancer. A study of the Eastern Cooperative Oncology Group. J. Clin. Oncol., 7, 1602-1613.
4. CERNY T, KAPLAN S AND PAVLIDIS N. (1994). Docetaxel (Taxotere) is active in non-small-cell-lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG). Br. J. Cancer, 70, 384-387.
5. COHEN MH AND PEREVODCHIKOVA NI. (1979). Single agent chemotherapy of lung cancer. In Lung Cancer: Progress in Therapeutic Research Muggia FM and Rozenczweig M (eds) pp. 343-374, Raven Press: New York.
6. HENDRIKS HR, PLOWMAN J, BERGER DP, PAULL KD, FIEBIG HH, FODSTAD O, DREEF VAN DER MEULEN HC, HENRAR REC, PINEDO HM AND SCHWARTSMANN G. (1992). Preclinical antitumour activity and animal toxicology studies of Rhizoxin, a novel tubulin-interacting agent. Ann. Oncol., 3, 755-763.
7. JOSS RA, CAVALLI F AND GOLDHIRSCH A. 1984). New agents in non-small-cell-lung cancer. Cancer Treat. Rev., 11, 205-236.
8. RAPP E, PATER JL, WILLAN A, CORMIER Y, MURRAY N, EVANS WK, HODSON DA, CLARK DA, FELD R, ARNOLD AM, AYOUB JI, WILSON KS, LATREILLE J, WIERZBICKI RF AND HILL DP. (1988). Chemotherapy can prolong survival in patients with advanced non-small-cell-lung cancer - Report of a Canadian multicentre randomised trial. J. Clin. Oncol., 6, 633-641.
9. 0 non-small-cell-lung cancer. Ann. Thorac. Surg., 49, 242-247.
10. TSURUO T, OHARA T, LIDA H, TSUKAGOSHI S, SATO Z, MATSUDA I, IWASAKI S, OKUDA S, SHIMIZU F, SASAGAWA K, FUKAMI M, FUKUDA K AND ARAKAWA M. (1986). Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res., 46, 381-385.